Exelixis | EXEL - Interest Income


Exelixis reported $16.79M in Interest Income for its fiscal quarter ending in June of 2025.





Interest Income Change Date
Acadia Pharmaceuticals USD 7.24M 658K Jun/2025
Agios Pharmaceuticals USD 14.51M 1.57M Jun/2025
AstraZeneca USD 68M 16M Jun/2025
Bayer EUR 130M 38M Sep/2025
BioMarin Pharmaceutical USD 18.83M 186K Jun/2025
Cytokinetics USD 13M 700K Jun/2025
Eisai JPY 3.11B 783M Mar/2024
Eli Lilly USD 65M 25M Sep/2025
Genmab DKK 25M 8M Jun/2025
Glaxosmithkline GBP 26M 24M Sep/2025
Incyte USD 25.14M 2.21M Jun/2025
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
MacroGenics USD 1.53M 114K Sep/2025
Merck USD 96M 27M Sep/2025
Moderna USD 81M 9M Jun/2025
Pfizer USD 0.62 156M Sep/2025
Sanofi EUR 114M 38M Sep/2025
Takeda JPY 87.87B 43.48B Dec/2025
Ultragenyx Pharmaceutical USD 5.79M 1.04M Jun/2025
Xencor USD 7.25M 290K Jun/2025